Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

BACKGROUND: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for treatment of relapsing forms of MS. OBJECTIVE: To characterize long-term safety and efficacy of ozanimod. METHODS: Patients with relapsing MS who completed a phase 1‒3 ozanimod tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Cree, Bruce AC, Selmaj, Krzysztof W, Steinman, Lawrence, Comi, Giancarlo, Bar-Or, Amit, Arnold, Douglas L, Hartung, Hans-Peter, Montalbán, Xavier, Havrdová, Eva K, Sheffield, James K, Minton, Neil, Cheng, Chun-Yen, Silva, Diego, Kappos, Ludwig, Cohen, Jeffrey A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493410/
https://www.ncbi.nlm.nih.gov/pubmed/35765217
http://dx.doi.org/10.1177/13524585221102584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493410/
https://www.ncbi.nlm.nih.gov/pubmed/35765217
http://dx.doi.org/10.1177/13524585221102584

Ejemplares similares